Supplemental material
Current Medical Research and Opinion
Volume 32, 2016 - Issue 8
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Insulin resistance and fractures.
Source:
Wiley
Diabetes Mellitus Is Associated With an Increased Risk of Falls in Elderly Residents of a Long-Term Care Facility
Source:
Oxford University Press (OUP)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Source:
Wiley
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
Source:
American Diabetes Association
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Source:
The Endocrine Society
Possible adverse effects of SGLT2 inhibitors on bone.
Source:
Elsevier BV
Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial
Source:
Informa UK Limited
Diabetes Medications Related to an Increased Risk of Falls and Fall-Related Morbidity in the Elderly
Source:
SAGE Publications
Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.
Source:
Informa UK Limited
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Source:
Springer Science and Business Media LLC
Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Source:
Springer Nature
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
Source:
Informa Healthcare
Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community.
Source:
Elsevier BV
Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
Source:
American Diabetes Association
A Randomized Controlled Trial
Source:
American Medical Association (AMA)
Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
Source:
Elsevier BV
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
Source:
American Diabetes Association
Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy.
Source:
Associação Médica Brasileira
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.
Source:
Springer Science and Business Media LLC
Older women with diabetes have a higher risk of falls: a prospective study.
Source:
American Diabetes Association
The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
Source:
Elsevier BV
Transgenic Mice Expressing Fibroblast Growth Factor 23 under the Control of the α1(I) Collagen Promoter Exhibit Growth Retardation, Osteomalacia, and Disturbed Phosphate Homeostasis
Source:
The Endocrine Society
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
Source:
Wiley
Successful Integration of Nonclinical and Clinical Findings in Interpreting the Clinical Relevance of Rodent Neoplasia with a New Chemical Entity
Source:
SAGE Publications
Drugs Causing Bone Loss.
Source:
Springer
Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies.
Source:
Japanese Society for the Study of Xenobiotics
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Source:
Public Library of Science (PLoS)
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Source:
Springer Nature
Fibroblast growth factor-23: what we know, what we don't know, and what we need to know
Source:
Oxford University Press (OUP)
Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.
Source:
SAGE Publications
Linking provided by
